Skip Navigation


JAC Advance Access originally published online on October 11, 2005
Journal of Antimicrobial Chemotherapy 2005 56(6):1181-1182; doi:10.1093/jac/dki381
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
56/6/1181    most recent
dki381v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Johnson, A. P.
Right arrow Articles by George, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, A. P.
Right arrow Articles by George, R. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Correspondence

Susceptibility of pneumococci causing meningitis in England and Wales to first-line antimicrobial agents, 2001–2004

Alan P. Johnson1,*, Nicola Potz1, Pauline Waight1, Usha Gungabissoon2, David M. Livermore3, Richard Pebody2, Elizabeth Miller2 and Robert C. George4

1 Department of Healthcare-Associated Infection and Antimicrobial Resistance, Health Protection Agency Centre for Infections, London NW9 5EQ, UK; 2 Immunisation Department, Health Protection Agency Centre for Infections, London NW9 5EQ, UK; 3 Antibiotic Resistance Monitoring and Reference Laboratory, Health Protection Agency Centre for Infections, London NW9 5HT, UK; 4 Respiratory and Systemic Infection Laboratory, Health Protection Agency Centre for Infections, London NW9 5HT, UK

* Corresponding author: Tel: +44-20-8327-6043; Fax: +44-20-8205-9185; E-mail: alan.johnson@hpa.org.uk

Keywords: therapy , surveillance , pneumococcal

The first 10% of the full text of this article appears below.

Sir,

Historically, penicillin was the drug of choice for treating pneumococcal infections, including meningitis, but strains with reduced susceptibility have been reported worldwide over the last four decades.1 Although pneumococcal pneumonia remains amenable to treatment with high-dose penicillin, even when caused by non-susceptible strains,2 any degree of penicillin non-susceptibility (MIC ≥ 0.12 mg/L) is associated with a likelihood of treatment failure in pneumococcal meningitis due to the poor penetration of penicillin into CSF.1 Cefotaxime and ceftriaxone have better pharmacodynamic profiles than penicillin . . . [Full Text of this Article]

Transparency declarations


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?